| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
ACE (angiotensin-converting enzyme), α-glucosidase, PTP1B (protein tyrosine phosphatase 1B), and RLAR (rat lens aldose reductase). Vicenin 2 inhibits ACE with an IC50 of 43.83 μM. It also inhibits α-glucosidase, PTP1B, and RLAR. It has been identified as a potential TMPRSS2 antagonist and targets GSK3β to reduce inflammation and apoptosis.
|
|---|---|
| ln Vitro |
In NCI-H23 cells, vicenin 2 (10–100 µM; 24 hours) exhibits cytotoxic effects that increase with dosage. Vicenin 2 is harmless to fibroblasts and has radioprotective properties. It can raise caspase-3 activity, increase DNA fragmentation, increase Rad50 levels, and decrease MMP-2 and p21 protein levels [2].
Vicenin 2 exhibits cytotoxic effects on NCI-H23 cells at concentrations ranging from 10 to 100 µM over 24 hours, with effects increasing with dosage. It is harmless to fibroblasts and has radioprotective properties. It can increase caspase-3 activity, increase DNA fragmentation, increase Rad50 levels, and decrease MMP-2 and p21 protein levels. It modifies LPS-induced total nitrite and TNF-α production and LPS-induced translocation of NF-κB. |
| ln Vivo |
In DSS-induced ductal inflammation, vicenin 2 (50 mg/kg; lung; for 7 days) efficiently lowers MPO activity and inhibits the expression of pro-inflammatory cytokines and other critical indicators [3].
Vicenin 2 effectively lowers MPO activity and inhibits the expression of pro-inflammatory cytokines and other critical indicators in DSS-induced colitis at an oral dose of 50 mg/kg for 7 days. It has radioprotective, antinociceptive, anti-glycation, anti-inflammatory, antioxidant, anti-cancer, and anti-angiogenic properties. It shows potential for the treatment of diabetes and diabetes-associated complications. |
| Enzyme Assay |
Vicenin 2 is evaluated in cell-free enzymatic assays using purified ACE, α-glucosidase, PTP1B, and RLAR enzymes. The compound is incubated with each enzyme and its respective substrate, and the inhibition of enzyme activity is measured. IC50 values are determined to quantify the potency of inhibition. ACE inhibition is measured at an IC50 of 43.83 μM.
|
| Cell Assay |
Cell viability assay[2]
Cell Types: NCI-H23 Cell Tested Concentrations: 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, 60 µM, 70 µM, 80 µM, 90 µM, 100 µM Incubation Duration: 24 hrs (hours) Experimental Results: demonstrated cytotoxic effect on NCI-H23 cells. Vicenin 2 is assessed in cell-based assays using NCI-H23 cells. Cells are treated with Vicenin 2 at concentrations ranging from 10 to 100 µM for 24 hours. Cytotoxicity is measured using cell viability assays. The compound exhibits cytotoxic effects that increase with dosage. It is harmless to fibroblasts and has radioprotective properties. It increases caspase-3 activity, DNA fragmentation, and Rad50 levels, while decreasing MMP-2 and p21 protein levels. |
| Animal Protocol |
Animal/Disease Models: Male C57BL/dextran sodium sulfate (DSS)-treated 6J mice (25g)[3]
Doses: 50mg/kg Route of Administration: Oral; continued for 7 days Experimental Results: Effectively inhibited DSS by attenuating the expression of key inflammatory mediators Induced colitis. Vicenin 2 is administered orally in male C57BL/6 mice at a dose of 50 mg/kg for 7 days. The compound effectively inhibits DSS-induced colitis by attenuating the expression of key inflammatory mediators. It lowers MPO activity and inhibits the expression of pro-inflammatory cytokines. The compound is orally bioactive, suggesting good bioavailability. |
| ADME/Pharmacokinetics |
Vicenin 2 is an orally active compound with good bioavailability. It has a molecular weight of 594.52. The compound is a flavonoid with radioprotective, antinociceptive, anti-glycation, anti-inflammatory, antioxidant, anti-cancer, and anti-angiogenic properties. It is soluble in DMSO and should be stored away from direct sunlight. The compound has a density of 1.758 g/cm3.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Vicenin 2. The compound is for research use only and is not intended for human therapeutic use. It has been shown to have no absorption and no efflux in Caco-2 cells, suggesting limited intestinal permeability. The compound is a flavonoid with a wide range of biological activities and is considered a useful lead for the development of multiple target-oriented therapeutic modalities.
|
| References |
|
| Additional Infomation |
Isovitexin 8-C-β-glucoside is a C-glycoside compound with the structure Isovitexin, where the 8th hydrogen atom is replaced by a β-D-glucose residue. It is a metabolite belonging to the trihydroxyflavonoid class and the C-glycoside class, and is functionally related to Isovitexin. Vesenin-2 has been reported in tea (Camellia sinensis), burdock (Acanthus ebracteatus), and other organisms with relevant data.
Vicenin 2 is a flavonoid and an orally active ACE inhibitor (IC50 of 43.83 μM) derived from Desmodium styracifolium. It is also known as apigenin 6,8-di-C-glucoside or vicenin II. The compound has a molecular weight of 594.52 and a molecular formula of C27H30O15. It has a CAS number of 23666-13-9. It exhibits hepatoprotective, anti-cancer, antioxidant, anti-inflammatory, radioprotective, antinociceptive, anti-glycation, and anti-angiogenic properties. It is used for research purposes only and has not been approved for clinical use. |
| Molecular Formula |
C27H30O15
|
|---|---|
| Molecular Weight |
594.52
|
| Exact Mass |
594.158
|
| CAS # |
23666-13-9
|
| PubChem CID |
442664
|
| Appearance |
White to yellow solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
974.7±65.0 °C at 760 mmHg
|
| Flash Point |
323.7±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.749
|
| LogP |
-0.1
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
42
|
| Complexity |
987
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C(=C3O2)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O
|
| InChi Key |
FIAAVMJLAGNUKW-VQVVXJKKSA-N
|
| InChi Code |
InChI=1S/C27H30O15/c28-6-12-17(32)21(36)23(38)26(41-12)15-19(34)14-10(31)5-11(8-1-3-9(30)4-2-8)40-25(14)16(20(15)35)27-24(39)22(37)18(33)13(7-29)42-27/h1-5,12-13,17-18,21-24,26-30,32-39H,6-7H2/t12-,13-,17-,18-,21+,22+,23-,24-,26+,27+/m1/s1
|
| Chemical Name |
5,7-dihydroxy-2-(4-hydroxyphenyl)-6,8-bis[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
|
| Synonyms |
Vicenin2 Vicenin-2 Vicenin 2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~56.06 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6820 mL | 8.4101 mL | 16.8203 mL | |
| 5 mM | 0.3364 mL | 1.6820 mL | 3.3641 mL | |
| 10 mM | 0.1682 mL | 0.8410 mL | 1.6820 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
